A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
New England Journal of Medicine · 22.01.2026 · 394 (4) · 343-353
DOI: 10.1056/nejmoa2508827 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 22.01.2026. Verfasst von Tarik Asselah und 17 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Cité, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, INSERM Unité Mixte de Recherche 1149, Paris. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antiviral Agents, Hepatitis D, Chronic, Hepatitis Delta Virus. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Vir Biotechnology.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris-Cité, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, INSERM Unité Mixte de Recherche 1149, Paris.
- Vir Biotechnology, San Francisco.
- Arensia Exploratory Medicine, Düsseldorf, Germany.
- Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova.
- National Institute for Infectious Diseases Matei Balş, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan.
ORCID-Profile: Tarik Asselah
Förderung
- Vir Biotechnology
Zitieren
APA
Asselah, T., Chattergoon, M. A., Jucov, A., Streinu-Cercel, A., Lampertico, P., Wedemeyer, H., Kennedy, P. T., Gane, E. J., Bullard, B. L., Chow, S., Santos, D., Camus, G., Lu, Y., Pilowa, C., Hwang, C., Correll, T., Agarwal, K., & SOLSTICE Trial Investigators (2026). A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D. New England Journal of Medicine, 394(4), 343-353. https://doi.org/10.1056/nejmoa2508827
Vancouver
Asselah T, Chattergoon MA, Jucov A, Streinu-Cercel A, Lampertico P, Wedemeyer H, et al. A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D. New England Journal of Medicine. 2026;394(4):343-353. doi:10.1056/nejmoa2508827
BibTeX
@article{Asselah2026,
author = {Asselah, Tarik and Chattergoon, Michael A and Jucov, Alina and Streinu-Cercel, Anca and Lampertico, Pietro and Wedemeyer, Heiner and Kennedy, Patrick T and Gane, Edward J and Bullard, Brianna L and Chow, Sophia and Santos, Desiree and Camus, Gregory and Lu, Yimeng and Pilowa, Cara and Hwang, Carey and Correll, Todd and Agarwal, Kosh and SOLSTICE Trial Investigators, SOLSTICE Trial Investigators},
title = {A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {4},
pages = {343--353},
doi = {10.1056/nejmoa2508827}
}
EUVIMED